Available in Brazil
The purpose of this study is to assess the efficacy and safety of rilvegostomig in
combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab,
chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic
gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1.
Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a
separate arm (Arm C) to assess the contribution of each component in the experimental
arm.
This study will be conducted at up to 200-250 sites globally in approximately 25
countries.
840Patients around the world